Testing to treatment of BRAF-mutant metastatic NSCLC

In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.

The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients. Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.

The experts also discuss how to treat patients who have co-mutations detected during testing.

This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC.

Key clinical takeaways:

• Test all patients irrespective of histology and smoking history

• Test upfront so that more efficacious agents can be used earlier in the patient journey

• Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed

• There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY

Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/lungconnect/

X: https://x.com/lung_connect

This content is intended for healthcare professionals outside of the UK only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre

This podcast is developed by https://cor2ed.com/

Published November 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:

• Current first-line systemic treatment options for uHCC
• Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs
• How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations

Key clinical takeaways:

• Two first-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen ( single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary.
• In clinical practice, treatment choice should be individualized, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/hcc-connect

X: https://x.com/hccconnectinfo

This content is intended for healthcare professionals only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.

This podcast is developed by cor2ed.com

Published on November 2024

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.

They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.

Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF mutated CRC.

The discussion also looks at future studies including the BREAKWATER trial, which will provide important information about encorafenib plus cetuximab in the first-line for these patients, as well as the SEAMARK trial which will show the effects of adding immunotherapy to this combination.

Key clinical takeaways:

• BRAF mutations occur in around 10% of colorectal cancer patients and patients harbouring these have aggressive disease and a poor prognosis

• Targeted therapies are available for BRAF-mutated CRC so it is important to test patients early in their disease preferably with next-generation sequencing

• Encorafenib plus cetuximab are established as the standard of care in the second-line setting for BRAF-mutated CRC

• Doublet chemotherapy plus anti-VEGF is currently the preferred treatment in the first-line. The BREAKWATER trial will determine whether the combination of encorafenib plus cetuximab is a suitable first-line treatment option

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/Pp7oAI9JW4A

Download the transcript and find out more about this programme and the featured experts here: https://cor2ed.com/gi-connect/programmes/braf-mutated-crc-testing-treatment/

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/giconnect

X: https://x.com/giconnectInfo

This content is intended for healthcare professionals outside of the UK only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre

This podcast was developed by https://cor2ed.com/

Published November 2024

Subscribe to this channel to stay up to date with new Independent Edu...